235 related articles for article (PubMed ID: 28747357)
1. An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease.
Yanda MK; Liu Q; Cebotaru L
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F997-F1004. PubMed ID: 28747357
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
[TBL] [Abstract][Full Text] [Related]
3. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
[TBL] [Abstract][Full Text] [Related]
6. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
J Alzheimers Dis; 2014; 41(4):1193-205. PubMed ID: 24844691
[TBL] [Abstract][Full Text] [Related]
7. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
8. Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease.
Wang Q; Cobo-Stark P; Patel V; Somlo S; Han PL; Igarashi P
Kidney Int; 2018 Feb; 93(2):403-415. PubMed ID: 29042084
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
He J; Zhang S; Qiu Z; Li X; Huang H; Jin W; Xu Y; Shao G; Wang L; Meng J; Wang S; Geng X; Jia Y; Li M; Yang B; Jenny Lu HA; Zhou H
J Am Soc Nephrol; 2021 Sep; 32(9):2159-2174. PubMed ID: 34465607
[TBL] [Abstract][Full Text] [Related]
10. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Wu M; Mei C
Kidney Int; 2016 Jul; 90(1):20-2. PubMed ID: 27312442
[TBL] [Abstract][Full Text] [Related]
12. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Yanda MK; Liu Q; Cebotaru L
J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.
Fan LX; Li X; Magenheimer B; Calvet JP; Li X
Kidney Int; 2012 Jan; 81(1):76-85. PubMed ID: 21900881
[TBL] [Abstract][Full Text] [Related]
14. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics and autosomal dominant polycystic kidney disease.
Li X
Biochim Biophys Acta; 2011 Oct; 1812(10):1213-8. PubMed ID: 20970496
[TBL] [Abstract][Full Text] [Related]
16. Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.
Cao X; Fan Z; Xu L; Zhao W; Zhang H; Yang Y; Ren Y; Xiao Y; Zhou N; Yin L; Zhou X; Zhu X; Guo D
Eur J Med Chem; 2024 May; 271():116428. PubMed ID: 38653068
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway.
Zhang WB; Zhang HY; Jiao FZ; Wang LW; Zhang H; Gong ZJ
Biomed Pharmacother; 2018 Jan; 97():818-824. PubMed ID: 29112935
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.
Liu W; Fan LX; Zhou X; Sweeney WE; Avner ED; Li X
PLoS One; 2012; 7(11):e49418. PubMed ID: 23152903
[TBL] [Abstract][Full Text] [Related]
19. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Sakloth F; Manouras L; Avrampou K; Mitsi V; Serafini RA; Pryce KD; Cogliani V; Berton O; Jarpe M; Zachariou V
Psychopharmacology (Berl); 2020 Jul; 237(7):2139-2149. PubMed ID: 32388618
[TBL] [Abstract][Full Text] [Related]
20. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.
Zhou X; Fan LX; Sweeney WE; Denu JM; Avner ED; Li X
J Clin Invest; 2013 Jul; 123(7):3084-98. PubMed ID: 23778143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
